Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)

Article ID	Journal	Published Year	Pages	File Type
8793982	Ophthalmology	2018	10 Pages	PDF

Abstract

Treatment with RBZ+PRP was more effective than PRP monotherapy for NV regression in HR-PDR participants over 12 months.

Keywords

ITV PDR NVD logMAR BCVA ETDRS HbA1c NVE PrP FAS DME RBZ NVT panretinal photocoagulation Diabetic macular edema standard deviation best-corrected visual acuity full analysis set intravitreal per protocol early treatment diabetic retinopathy study ranibizumab Proliferative diabetic retinopathy adverse event Vascular endothelial growth factor Vascular Endothelial Growth Factor (VEGF)logarithm of the minimum angle of resolution disc area Neovascularization Glycated hemoglobin

Related Topics

Health Sciences Medicine and Dentistry Ophthalmology

Preview

Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)

Authors

JoÃ£o MD, PhD, Emily MB ChB, FRCOphth, Pascale MD, PhD, Rufino MD, PhD, Francesco MD, PhD, Edoardo MD, PhD, Monica MD, Sobha MD, FRCOphth, Haralabos MD, Geeta MBBS, MS, Miguel MD, Sarah MD, PhD, Catherine MD, PhD, JoÃ£o MD, Dalila MSc, Sandrina PhD,